Advances in Therapy · 2019 · 19 citations · 20 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacovigilanceCardiac PharmacotherapyCardiovascular DiseaseCardiovascular Drug SafetyCardiovascular PharmacologyClinical TrialsSodium-glucose Cotransporter 2 InhibitorsAdverse Cardiovascular Drug EventsBlood Pressure Adverse EffectsClinical Trial Safety AnalysisPrevention Of Cardiovascular Complications
20
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text
Melanie J. Davies, David A. D’Alessio, Judith Fradkin et al. · Diabetes Care · 2018 · 3.5K citations · Full text